Journal Club tomorrow evening!
Nina DiPrimio
Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes, et al.
Summary: Background Immunisation of patients with Alzheimer’s disease with full-length amyloid-β peptide (Aβ42) can clear amyloid plaques from the brain. Our aim was to assess the relation between Aβ42 immune response, degree of plaque removal, and long-term clinical outcomes.
One claim made in the paper is that patients "with virtually complete plaque removal, had severe end stage dementia." John would like us to discuss this claim, and determine if really supported by the data. If yes, how? If not, what else might the data mean?
Look forward to a wonderful discussion. Please make sure to make a zoom.us account to join the discussion.
Zoom link to the meeting: https://zoom.us/j/189777898
The paper is attached.
Nina DiPrimio, PhD
Anderson Lab
Department of Bioengineering
UC Berkeley
Lab Phone- 510-664-4200